Evofem Biosciences EBITDA 2013-2022 | EVFM

Evofem Biosciences ebitda from 2013 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Evofem Biosciences Annual EBITDA
(Millions of US $)
2021 $-166
2020 $-103
2019 $-52
2018 $-77
2017 $-35
2016 $-12
2015 $-42
2014 $-10
2013 $-14
2012 $-6
Evofem Biosciences Quarterly EBITDA
(Millions of US $)
2022-03-31 $-29
2021-12-31 $-37
2021-09-30 $-43
2021-06-30 $-41
2021-03-31 $-45
2020-12-31 $-36
2020-09-30 $-26
2020-06-30 $-22
2020-03-31 $-19
2019-12-31 $-13
2019-09-30 $-14
2019-06-30 $-12
2019-03-31 $-14
2018-12-31 $-15
2018-09-30 $-18
2018-06-30 $-23
2018-03-31 $-21
2017-12-31 $-15
2017-09-30 $-9
2017-06-30 $-6
2017-03-31 $-5
2016-12-31 $-2
2016-09-30 $-2
2016-06-30 $-3
2016-03-31 $-6
2015-12-31 $-9
2015-09-30 $-17
2015-06-30 $-9
2015-03-31 $-7
2014-12-31 $-3
2014-09-30 $-2
2014-06-30 $-2
2014-03-31 $-2
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.014B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00